FENNEC PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.09 USD | -0.98% |
|
+0.22% | -18.98% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.63 times its estimated earnings per share for the ongoing year.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -18.98% | 249M | D+ | ||
| -1.17% | 102B | B+ | ||
| +2.87% | 96.09B | B+ | ||
| +2.13% | 22.28B | B | ||
| -14.77% | 21.4B | B+ | ||
| -8.79% | 18.14B | A- | ||
| -39.98% | 17.02B | A- | ||
| -13.21% | 16.09B | B | ||
| +8.55% | 13.83B | C+ | ||
| +35.75% | 11.97B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- FENC Stock
- Ratings Fennec Pharmaceuticals Inc.
